Lupus: Novel therapies in clinical development
- 作者：Preeta Kaur Chugh ; docpreeta@yahoo.com
- 关键词：Systemic lupus erythematosus ; Belimumab ; Anti-B cell therapy ; Immunosuppressant ; Clinical trial
- 刊名：European Journal of Internal Medicine
- 出版年：2012
- 期刊代码：91_09536205
- 类别：med
- 出版时间：April, 2012
- 卷：23
- 期：3
- 页码：212-218
- 文件大小：368 K
摘要
There have been significant advancements in understanding the immunopathogenesis of systemic lupus erythematosus. However, the developments in therapeutics have been rather slow. Belimumab, a B lymphocyte stimulator (BLyS) inhibitor has been approved for the treatment of this disease after more than 50 years. Numerous biological agents are being developed which target the B cells, T cells, and various cytokines. Among anti-B cell therapy, drugs target CD20 + cells (ocrelizumab, SBI-087), CD22 + cells (epratuzumab) \or the receptors of tumor necrosis factor (TNF) superfamily (atacicept, LY2127399, A-623). Monoclonal antibodies targeting interferon alpha (IFN-伪) and gamma (IFN-纬) and interleukins (IL-6, 10) are being investigated for SLE. Novel targets include toll like receptors, phosphodiesterases, CD40 ligand and retinoid receptors. This review discusses various drugs which are in different phases of clinical trials and hold promise for patients suffering from this chronic debilitating disease.